Alligator Bioscience has appointed Dr Christina Reimer as Chief Medical Officer.
Dr Reimer will replace Dr Charlotte Russel and be overall medically responsible for Alligator’s drug development candidates, with an emphasis on bringing mitazalimab and ATOR-1017 into Phase II efficacy studies. She will report to Head of R&D, EVP Malin Carlsson, and be part of the management team. Reimer most recently comes from a position as Senior Medical Director at Ferring Pharmaceuticals in Copenhagen.
“I am very pleased with the successful recruitment of Christina Reimer to Alligator. Her international experience in leading clinical development and in building development organizations will significantly strengthen our clinical capacity. This is crucial in the phase we are in now, with two products on the way to Phase II and another product in clinical Phase I. We look forward to welcoming Christina to Lund and to our management team,” says Per Norlén, CEO of Alligator Bioscience.
Experience from leading clinical programs within the industry
Christina Reimer is a medical doctor with specialist qualifications and a PhD in gastroenterology. She also has considerable experience from leading clinical programs within the industry. Christina Reimer will assume the role of Chief Medical Officer (CMO) at Alligator on February 1, 2021.
“Alligator’s solid science-based approach to discover new cancer treatments and the fact that they have several assets in clinical development is what makes this opportunity unique. I hope to be able to apply my many years of clinical experience with cancer patients and my clinical drug development skills to progress Alligator’s assets through the next important steps of development. I look very much forward to become part of the team at Alligator,” says Christina Reimer.